Prothena Corporation plc: Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
Prothena reported Q3 2026 net loss of $16.5M and 9M net loss of $2.4M, with $272.2M in cash. Coramitug showed reduced hsCRP in Phase 2 trial. Roche and Novo highlight prasinezumab and coramitug for Parkinson's and ATTR-CM. Phase 3 trials expected to complete in 2029. Prothena has $650M in upfront payments and potential $2.25B in milestones. Preclinical programs include TDP-43 CYTOPE and PRX012-TfR.
How this was made
The 30-second read
Why it matters
The trial data could de‑risk the program and support higher valuation, while the cash balance reduces near‑term financing concerns.
Market read
Earnings plus early trial data provide fresh material for investors; likely short‑term price movement.
What to watch
Milestone payments from Novo are a one‑time boost; future cash flow depends on later trial readouts and regulatory approvals.
Background
Prothena, a Nasdaq‑listed biotech, released its Q3 2026 financials and highlighted new Phase 2 biomarker data for its coramitug program targeting ATTR‑CM.
Ticker impact
Prothena reported Q3 2026 results and disclosed post‑hoc Phase 2 data showing an ~8% hsCRP decrease for coramitug versus a 33% increase on placebo.
potential upside as market prices in the favorable coramitug data and cash runway
First disclosure of trial biomarker results and a sizable cash balance; biotech stocks typically react positively to early‑stage efficacy signals.
Market effects
May lift other amyloidosis and neuro‑degeneration biotech peers as the data suggest a viable therapeutic pathway.
Limited to US‑listed biotech sector; no broader regional effect.
Modest, confined to specialty biotech investors.
Counterpoint
The biomarker endpoint is surrogate; efficacy in clinical outcomes remains unproven, so price may be overstated.
Key entities
- companyProthena Corporation plc
Late‑stage biotech reporting earnings and trial updates.
